



Name	He Huang	
Current Position	President of the First Affiliated Hospital, Zhejiang University School of Medicine; Director of Hematology Institution of Zhejiang University	
Country	China	
Major Field	Hematopoietic stem cell transplantation; Cellular immunotherapy and stem cell biology research	

Educational Background

1979 - 1984 Bachelor of Medicine, Zhejiang University School of Medicine, Hangzhou, China

1987 - 1990 Master of Medicine, Zhejiang University School of Medicine, Hangzhou, China

1990 - 1993 M.D. and Ph.D., Zhejiang University School of Medicine, Hangzhou, China

Professional Experience

1984 - 1987 Resident, Internal Medicine, Jinhua Center Hospital, Zhejiang, China

1993 - 1997 Physician, Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, China

1997 Advanced Visiting Scholar, Institute of Hematopathology, Kiel University, Germany

1997 - 2000 Vice Director, Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, China

2000 - present Professor, Zhejiang University School of Medicine, China

2000 - present Director, Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, China



2005 – 2020 Associate Dean, Zhejiang University School of Medicine, China
2016 – present Director, Institute of Hematology, Zhejiang University, China
2020– present President of the First Affiliated Hospital, Zhejiang University School of Medicine, China

Other Experience and Professional Memberships

Vice Chairman of Experts Committee of Chinese Marrow Donor Program
Executive Committee member of Asia-Pacific Bone Marrow Transplantation Group (APBMT)
Vice Chairman of Committee member of Asian Cellular Therapy Organization (ACTO)
Global committee member of European Society of Hematology (EBMT)

Main Scientific Publications

As corresponding author, Prof. He Huang has published 251 original papers in SCI-cited journals including Nature, Cell Research, Lancet Haematol etc.

Representative papers:

1. Zhang J, Hu Y, Yang J, Li W, Zhang M, Wang Q, Zhang L, Wei G, Tian Y, Zhao K, Chen A, Tan B, Cui J, Li D, Li Y, Qi Y, Wang D, Wu Y, Li D*, Du B*, Liu M*, Huang H*. Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL. Nature. 2022 Sep;609(7926):369-374.
 2. Hu Y, Zhou Y, Zhang M, Zhao H, Wei G, Ge W, Cui Q, Mu Q, Chen G, Han L, Guo T, Cui J, Jiang X, Zheng X, Yu S, Li X, Zhang X, Chen M, Li X, Gao M, Wang K, Zu C, Zhang H, He X, Wang Y, Wang D, Ren J, Huang H*. Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study. Cell Res. 2022 Nov;32(11):995-1007.
 3. Zhang M, Wei G, Zhou L, Zhou J, Chen S, Zhang W, Wang D, Luo X, Cui J, Huang S, Fu S, Zhou X, Tang Y, Ding X, Kuang J, He XP, Hu Y, Huang H*. GPR C5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial. Lancet Haematol. 2023 Feb;10(2):e107-e116.
-



-
4. Xu Y, Zeng X, Zhang M, Wang B, Guo X, Shan W, Cai S, Luo Q, Li H, Li X, Li X, Zhang H, Wang L, Lin Y, Liu L, Li Y, Zhang M, Yu X, Qian P*, Huang H*. Efficient expansion of rare human circulating hematopoietic stem/progenitor cells in steady-state blood using a polypeptide-forming 3D culture. *Protein Cell*. 2022 Nov;13(11):808-824.
 5. Hu Y, Li J, Ni F, Yang Z, Gui X, Bao Z, Zhao H, Wei G, Wang Y, Zhang M, Hong R, Wang L, Wu W, Mohty M, Nagler A, Chang AH, van den Brink MRM, Li MD, Huang H*. CAR-T cell therapy-related cytokine release syndrome and the therapeutic response is modulated by the gut microbiome in hematologic malignancies. *Nat Commun*. 2022 Sep 9;13(1):5313.
-